패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Geron Corporation 29 애널리스트 중 8 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Carter Gould	Barclays
Peter Lawson	Barclays
George Zavoico	B. Riley Securities, Inc.

Geron 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?

Is Geron (NASDAQ:GERN) A Risky Investment?

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

Recent updates

Geron Corporation Announces Positive CHMP Opinion for RYTELO (Ietelstat) for the Treatment of Adults with Transfusion-Dependent Anemia Due to Lower-Risk MDS

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

Consensus revenue estimates increase by 55%

Geron Corporation Appoints Joseph Eid as Executive Vice President, Research and Development

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron: A Post Earnings And Funding Announcement Assessment

Geron Corporation Announces New Data to Be Present at Upcoming ASH Annual Meeting Highlighting Potential of RYTELO (Imetelstat) in Myeloid Hematologic Malignancies

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Geron Corporation to Report Q3, 2024 Results on Nov 07, 2024

Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition

Geron Corporation Announces Chief Commercial Officer to Depart, Effective August 31, 2024

Geron Corporation to Report Q2, 2024 Results on Aug 08, 2024

Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?

Executive VP & COO notifies of intention to sell stock

Chairman of the Board notifies of intention to sell stock

Geron: Innovative Rytelo Enters A Challenging MDS Market

Geron Corporation Announces FDA Approval of RYTELO (imetelstat) for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q1, 2024 Results on May 02, 2024

Consensus revenue estimates decrease by 16%

Geron Corporation, Annual General Meeting, May 09, 2024

Geron Corporation has completed a Follow-on Equity Offering in the amount of $149.999995 million.

Price target increased by 7.0% to US$5.08

Consensus revenue estimates decrease by 13%

New major risk - Share price stability

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Geron Corporation Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Consensus revenue estimates decrease by 21%, EPS upgraded

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q4, 2023 Results on Feb 28, 2024

New minor risk - Share price stability

Forecast to breakeven in 2026

Geron Announces 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Consensus revenue estimates increase by 76%

Geron Corporation has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q3, 2023 Results on Nov 02, 2023

Geron Corporation Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Is Geron (NASDAQ:GERN) A Risky Investment?

Geron Corporation Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

Consensus revenue estimates fall by 14%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Geron Corporation to Report Q2, 2023 Results on Aug 03, 2023

Geron Corporation Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

Geron Corporation Announces Submission of New Drug Application to FDA for First-In-Class Telomerase Inhibitor Imetelstat

Geron Corporation Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

Geron Corporation Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Consensus revenue estimates increase by 29%

Geron Corporation Announces Board Changes

Consensus revenue estimates decrease by 48%, EPS upgraded

Geron Corporation Announces Five Abstracts Related to Imetelstat Accepts at European Hematology Association Annual Meeting

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Chairman of the Board notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

Price target increased to US$4.50

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Geron Corporation Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

Insufficient new directors